Loading clinical trials...
Loading clinical trials...
The actual role of POLE mutations in high-risk endometrial cancer is undetermined. The main question it aims to answer is: What is the prevalence of POLE mutations in high-risk endometrial cancer case? What is the impact of POLE mutations in real world high-risk endometrial cancer case?
All high-risk recurrent endometrial cancer cases who were treated in a tertiary referral center will be analyzed and subjected to POLE mutation analysis. In addition, survival analysis will be used to analyze the role of POLE mutations in women with high-risk endometrial cancer. We can answers the following. 1. What is the prevalence of POLE mutations in women with high-risk endometrial cancer? 2. What is the role of POLE mutations in real world high-risk endometrial cancer?
Age
All ages
Sex
FEMALE
Healthy Volunteers
No
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital
Banqiao District, New Taipei, Taiwan
Start Date
September 1, 2025
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
August 11, 2025
150
ESTIMATED participants
Lead Sponsor
Far Eastern Memorial Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions